COMMUNIQUÉS West-GlobeNewswire
-
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
16/02/2026 -
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board
16/02/2026 -
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
16/02/2026 -
Communiqué de presse : L’étude sur Beyfortus publiée dans la revue The Lancet Infectious Diseases montre ses bénéfices chez les nourrissons au-delà de la première saison du VRS
16/02/2026 -
Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470
16/02/2026 -
GN Store Nord A/S - Notice to convene the Annual General Meeting 2026
16/02/2026 -
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
16/02/2026 -
Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
15/02/2026 -
SCIENTIFICALLY UNREFUTED: A Breakthrough Invention Saving Millions of Lives and Billions of Dollars Awaits a Public Comparative Evaluation Within CPRIT’s $6 Billion Cancer Program
15/02/2026 -
BioRestorative Announces Closing of $5.0 Million Public Offering
14/02/2026 -
Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results
13/02/2026 -
SRX Health Solutions Inc. Announces Fiscal First Quarter 2026 Results for Quarter Ended December 31, 2025
13/02/2026 -
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/02/2026 -
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
13/02/2026 -
Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
13/02/2026 -
Paretofit Launches Digital Health Coaching System for Entrepreneurs in Europe’s DACH Region
13/02/2026 -
Inotiv Provides Notice Regarding Cybersecurity Incident
13/02/2026 -
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
13/02/2026 -
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
13/02/2026
Pages